CYKLOKAPRON® Highlights

(tranexamic acid)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use CYKLOKAPRON safely and effectively. See full prescribing information for CYKLOKAPRON.

CYKLOKAPRON (tranexamic acid) injection, for intravenous use
Initial U.S. Approval: 1986

INDICATIONS AND USAGE

CYKLOKAPRON is an antifibrinolytic indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. (1)

DOSAGE AND ADMINISTRATION

•
Before Extraction: Administer 10 mg/kg actual body weight of CYKLOKAPRON intravenously with replacement therapy. (2.1)
•
After Extraction: Administer 10 mg/kg actual body weight 3 to 4 times daily for 2 to 8 days. Infuse no more than 1 mL/minute to avoid hypotension. (2.1).
•
Reduce the dosage for patients with renal impairment. (2.2, 8.6)

DOSAGE FORMS AND STRENGTHS

•
Injection: 1,000 mg tranexamic acid (100 mg/mL) in 10 mL single-dose ampules (3)
•
Injection: 1,000 mg tranexamic acid (100 mg/mL) in 10 mL single-dose vials (3)

CONTRAINDICATIONS

•
In patients with subarachnoid hemorrhage, due to risk of cerebral edema and cerebral infarction. (4)
•
In patients with active intravascular clotting. (4)
•
In patients with severe hypersensitivity reactions to tranexamic acid or any of the ingredients. (4)

WARNINGS AND PRECAUTIONS

•
Risk of Thrombosis with Concomitant Use of Factor IX: Avoid concomitant use. (5.1)
•
Risk of Medication Errors Due to Incorrect Route of Administration: FOR INTRAVENOUS USE ONLY. (5.2)
•
Seizures: Inadvertent injection into neuraxial system may result in seizures. (5.3)
•
Hypersensitivity Reactions: In case of severe reaction, discontinue use and seek immediate medical attention. (5.4)
•
Visual Disturbances: Visual or ocular adverse effects may occur. Discontinue use if visual or ocular symptoms occur. (5.5)
•
Dizziness: Advise patients not to drive if dizziness occurs. (5.6)

ADVERSE REACTIONS

Most common adverse reactions are nausea, vomiting, diarrhea, allergic dermatitis, giddiness, hypotension, and thromboembolic events. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Prothrombotic Medical Products: Avoid concomitant use, can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid. (5.1, 7.1, 8.3)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 4/2024

Find CYKLOKAPRON® medical information:

Find CYKLOKAPRON® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

CYKLOKAPRON® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use CYKLOKAPRON safely and effectively. See full prescribing information for CYKLOKAPRON.

CYKLOKAPRON (tranexamic acid) injection, for intravenous use
Initial U.S. Approval: 1986

INDICATIONS AND USAGE

CYKLOKAPRON is an antifibrinolytic indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. (1)

DOSAGE AND ADMINISTRATION

•
Before Extraction: Administer 10 mg/kg actual body weight of CYKLOKAPRON intravenously with replacement therapy. (2.1)
•
After Extraction: Administer 10 mg/kg actual body weight 3 to 4 times daily for 2 to 8 days. Infuse no more than 1 mL/minute to avoid hypotension. (2.1).
•
Reduce the dosage for patients with renal impairment. (2.2, 8.6)

DOSAGE FORMS AND STRENGTHS

•
Injection: 1,000 mg tranexamic acid (100 mg/mL) in 10 mL single-dose ampules (3)
•
Injection: 1,000 mg tranexamic acid (100 mg/mL) in 10 mL single-dose vials (3)

CONTRAINDICATIONS

•
In patients with subarachnoid hemorrhage, due to risk of cerebral edema and cerebral infarction. (4)
•
In patients with active intravascular clotting. (4)
•
In patients with severe hypersensitivity reactions to tranexamic acid or any of the ingredients. (4)

WARNINGS AND PRECAUTIONS

•
Risk of Thrombosis with Concomitant Use of Factor IX: Avoid concomitant use. (5.1)
•
Risk of Medication Errors Due to Incorrect Route of Administration: FOR INTRAVENOUS USE ONLY. (5.2)
•
Seizures: Inadvertent injection into neuraxial system may result in seizures. (5.3)
•
Hypersensitivity Reactions: In case of severe reaction, discontinue use and seek immediate medical attention. (5.4)
•
Visual Disturbances: Visual or ocular adverse effects may occur. Discontinue use if visual or ocular symptoms occur. (5.5)
•
Dizziness: Advise patients not to drive if dizziness occurs. (5.6)

ADVERSE REACTIONS

Most common adverse reactions are nausea, vomiting, diarrhea, allergic dermatitis, giddiness, hypotension, and thromboembolic events. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Prothrombotic Medical Products: Avoid concomitant use, can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid. (5.1, 7.1, 8.3)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 4/2024
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.